BNTX – biontech se - american depositary shares (US:NASDAQ)
Stock Stats
News
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.
Form 6-K BioNTech SE For: Dec 18
Form 6-K BioNTech SE For: Dec 09
Form 6-K BioNTech SE For: Dec 06
Form 6-K BioNTech SE For: Dec 03
Form 144 BioNTech SE Filed by: Tureci Ozlem
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.